We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| GW Pharm. | LSE:GWP | London | Ordinary Share | GB0030544687 | ORD 0.1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 735.00 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
Hot Features
Premium
RNS Number:5668J
GW Pharmaceuticals PLC
28 September 2006
GW Pharmaceuticals plc
Institutional Investor Site Visit
Porton Down, UK, 28 September 2006 - GW Pharmaceuticals plc (AIM: GWP) will be
hosting an institutional investor site visit later today. The site visit will
include presentations given by senior managers and directors on GW's operations
and strategy. There will be no discussion about current trading or future
financial performance.
Enquiries:
GW Pharmaceuticals plc
Dr Geoffrey Guy, Executive Chairman + 44 (0)1980 557000
Justin Gover, Managing Director
Financial Dynamics Tel: +44 (0)20 7831 3113
David Yates, Sarah MacLeod
About GW Pharmaceuticals
GW was founded in 1998 and listed on the AiM, a market of the London Stock
Exchange in June 2001. Operating under license from the UK Home Office, the
company is developing cannabis-derived pharmaceutical products for patients with
multiple sclerosis, neuropathic pain, cancer pain, spinal cord injury,
rheumatoid arthritis, and other severe medical conditions.
GW has assembled a team of over 100 scientists with extensive experience in
developing both plant-based prescription pharmaceutical products and medicines
containing controlled substances. GW is dedicated to developing treatment
options that alleviate pain symptoms in patients who suffer from serious
ailments.
For further information, please visit the Company's website: www.gwpharm.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCPUUWCBUPQGCM
1 Year Gw Pharmaceuticals Chart |
1 Month Gw Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
